Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial
Cancer · 2026
DOI: 10.1002/cncr.70253 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Jiubing Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province, Glioma Clinical Diagnosis and…. Hauptthemen laut MEDLINE: Glioblastoma, Bevacizumab, Antibodies, Monoclonal, Humanized, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Research Foundation of the Health Commission of Henan Province, Henan Medical Science and Technology Research Youth Co-construction Project.
Abstract (Originalsprache)
Background
This study evaluated tislelizumab combined with low‐dose bevacizumab in recurrent glioblastoma (rGBM), assessing efficacy, safety, and mechanisms of immune escape.
Methods
This randomized phase 2 trial divided patients into treatment arms with distinct strategies. Longitudinal tumor in situ fluid (TISF) samples were collected for molecular analysis to monitor genome evolution. Immunohistochemical markers in paired primary and recurrent tumor specimens were analyzed to assess therapy‐induced immune resistance.
Results
A total of 109 patients were included, with 59 in the control group and 50 in the experimental group. No grade 4 adverse events or treatment discontinuations occurred in the experimental group. The experimental group demonstrated a median overall survival of 13.3 months, compared to 6.6 months in the control group. The objective response rate and disease control rate were 32.6% and 79.1%, respectively. Post‐treatment TISF analysis revealed a 68.4% reduction in detectable genomic alterations. Immunophenotypic analysis of paired tumor samples showed increased infiltration of CD163 + macrophages and elevated GDF‐15 expression in recurrent tumors.
Conclusion
This study shows that combining tislelizumab and low‐dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF‐based molecular markers reflect genomic evolution and predict prognosis. Increased CD163 + cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF‐15 levels may further suppress antitumor immunity, facilitating immune escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province, Glioma Clinical Diagnosis and Treatment Center of Henan Province, Zhengzhou University People's Hos…
- Department of Neurosurgery, Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province, Glioma Clinical Diagnosis and Treatment Center of Henan Province, Henan University People's Hospita…
- Department of Psychological Medicine, Henan Provincial People's Hospital, Zhengzhou, China.
- Department of Pathology, Henan Provincial People's Hospital, Zhengzhou, China.
- Department of Radiology, Zhengzhou University People's Hospital, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
ORCID-Profile: Jiubing Zhang, Dayang Wang, Xingyao Bu
Förderung
- Natural Science Foundation of Henan Province
- Research Foundation of the Health Commission of Henan Province
- Henan Medical Science and Technology Research Youth Co-construction Project
Zitieren
APA
Zhang, J., Wang, D., Liu, G., Bu, C., Lv, G., Li, M., Wei, S., Zhang, Z., Gao, Y., Yan, Z., Ma, C., Zhao, R., Wang, M., Shi, Y., & Bu, X. (2026). Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial. Cancer. https://doi.org/10.1002/cncr.70253
Vancouver
Zhang J, Wang D, Liu G, Bu C, Lv G, Li M, et al. Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial. Cancer. 2026. doi:10.1002/cncr.70253
BibTeX
@article{Zhang2026,
author = {Zhang, Jiubing and Wang, Dayang and Liu, Guanzheng and Bu, Chaojie and Lv, Guangming and Li, Minghao and Wei, Shaobin and Zhang, Ziyue and Gao, Yushuai and Yan, Zhaoyue and Ma, Chunxiao and Zhao, Ruijiao and Wang, Meiyun and Shi, Yujie and Bu, Xingyao},
title = {Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70253}
}
EUVIMED